Date: 2014-10-08
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at IDWeek 2014, being held October 8-12 in Philadelphia
Company: Tetraphase Pharmaceuticals (USA - MA)
Product: eravacycline (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline)
Action
mechanism: Eravacycline is a novel, fully synthetic tetracycline antibiotic with potent antibacterial activity against a broad spectrum of susceptible and multi-drug resistant bacteria. Eravacycline has demonstrated strong activity in vitro against Gram-positive pathogens, including both nosocomial and community-acquired methicillin susceptible or resistant Staphylococcus aureus strains, vancomycin susceptible or resistant Enterococcus faecium and Enterococcus faecalis, and penicillin susceptible or resistant strains of Streptococcus pneumoniae. In in vitro studies for cIAI, eravacycline consistently exhibited strong activity against enterococci and streptococci. One of the most frequently isolated anaerobic pathogens in cIAI, either as the sole pathogen or often in conjunction with another Gram-negative bacterium, is Bacteroides fragilis. In these studies eravacycline demonstrated activity against Bacteroides fragilis and a wide range of Gram-positive and Gram-negative anaerobes.
Disease:
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On October 8, 2014, Tetraphase Pharmaceuticals announced that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria. The researchers concluded that eravacycline, which is presently being studied in Phase 3 trials for complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), demonstrated excellent in vitro activity against Gram-negative MDR strains of E. coli, Klebsiella pnuemoniae, Enterobacter spp., and Acinetobacter baumannii (Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter Baumannii from New York City). In addition to the eravacycline poster, Tetraphase-sponsored research is highlighted via a second poster presentation related to Gram-negative MDR bacteria:\"Predictors of Hospital Mortality among Septic ICU Patients with Acinetobacter spp. bacteremia: A Cohort Study.\"
